Eli Lilly’s weight-loss drug tirzepatide, sold as Mounjaro and Zepbound, is no longer in shortage in the US, according to the FDA. The drugmaker has resolved the shortage by increasing production and working to meet demand, along with rival drugmaker Novo Nordisk. The market for these drugs is expected to grow significantly, prompting both companies to expand production and invest in new facilities.
Full Article
Donald Trump pauses tariffs on low-cost parcels in US-China trade reprieve
In response to US President Donald Trump's decision to cancel the tariff exemption on low-cost shipments from China, an amendment has temporarily paused the measure to allow time for an efficient collection system to be established. The de minimis provision, which exempts shipments under $800 from tariffs, will remain in place until adequate systems are in place. This move has caused turmoil for exporters and freight carriers, as well as concerns about the impact on...
Read more